Phase 2 Recurrent Lung Non-Small Cell Carcinoma trials recruiting now
All Recurrent Lung Non-Small Cell Carcinoma trials, every phase
6
Phase 2 recruiting
Other phases for Recurrent Lung Non-Small Cell Carcinoma
Phase 2 Recurrent Lung Non-Small Cell Carcinoma trials
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Common questions
What does Phase 2 mean?
Is this list complete?
No. For the full record, search ClinicalTrials.gov.